Body mass index influence interferon-beta treatment response in multiple sclerosis

J Neuroimmunol. 2015 Nov 15:288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

Abstract

Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI≥25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.

Keywords: Body mass index (BMI); Interferon-beta treatment; MRI disease activity; Multiple sclerosis; No evidence of disease activity; Treatment response.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Body Mass Index
  • Brain / pathology
  • Disease Progression
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Inflammation / etiology
  • Inflammation / pathology
  • Interferon-beta / therapeutic use*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / complications*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / pathology*
  • Obesity / complications*
  • Young Adult

Substances

  • Immunologic Factors
  • Interferon-beta